Orphazyme A/S Stock Forecast, Price & News

-0.81 (-11.05 %)
(As of 06/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume17.81 million shs
Average Volume3.97 million shs
Market Capitalization$227.89 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ORPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Orphazyme A/S and its competitors with MarketBeat's FREE daily newsletter.

Orphazyme A/S logo

About Orphazyme A/S

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.81 out of 5 stars

Medical Sector

1242nd out of 2,105 stocks

Pharmaceutical Preparations Industry

562nd out of 832 stocks

Analyst Opinion: 2.7Community Rank: 1.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Orphazyme A/S (NASDAQ:ORPH) Frequently Asked Questions

Is Orphazyme A/S a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orphazyme A/S in the last year. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" Orphazyme A/S stock.
View analyst ratings for Orphazyme A/S
or view top-rated stocks.

What stocks does MarketBeat like better than Orphazyme A/S?

Wall Street analysts have given Orphazyme A/S a "Sell" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Orphazyme A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Orphazyme A/S?

Orphazyme A/S saw a increase in short interest during the month of May. As of May 28th, there was short interest totaling 35,300 shares, an increase of 141.8% from the May 13th total of 14,600 shares. Based on an average trading volume of 182,600 shares, the days-to-cover ratio is presently 0.2 days.
View Orphazyme A/S's Short Interest

What price target have analysts set for ORPH?

3 brokerages have issued 1 year price objectives for Orphazyme A/S's stock. Their forecasts range from $5.00 to $27.00. On average, they anticipate Orphazyme A/S's stock price to reach $16.00 in the next year. This suggests a possible upside of 145.4% from the stock's current price.
View analysts' price targets for Orphazyme A/S
or view top-rated stocks among Wall Street analysts.

Who are Orphazyme A/S's key executives?

Orphazyme A/S's management team includes the following people:
  • Mr. Anders Fink Vadsholt M.B.A., M.Sc., MBA, Chief Financial Officer (Age 52, Pay $952.93k)
  • Mr. Christophe Bourdon M.B.A., Chief Exec. Officer (Age 51)
  • Dr. Thomas Kirkegaard Jensen Ph.D., Co-Founder & Chief Scientific Officer (Age 44)
  • Ms. Molly Poarch, Head of Global Communications
  • Dr. Thomas Blaettler, Chief Medical Officer (Age 54)
  • Ms. Molly Painter, Pres of US Orphazyme

Who are some of Orphazyme A/S's key competitors?

When did Orphazyme A/S IPO?

(ORPH) raised $100 million in an initial public offering (IPO) on Tuesday, September 29th 2020. The company issued 7,600,000 shares at $13.13 per share. BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO and Danske Markets was co-manager.

What is Orphazyme A/S's stock symbol?

Orphazyme A/S trades on the NASDAQ under the ticker symbol "ORPH."

Who are Orphazyme A/S's major shareholders?

Orphazyme A/S's stock is owned by a number of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (0.38%), Millennium Management LLC (0.35%), Caas Capital Management LP (0.06%) and Point72 Hong Kong Ltd (0.01%).

Which institutional investors are selling Orphazyme A/S stock?

ORPH stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, and Caas Capital Management LP.

Which institutional investors are buying Orphazyme A/S stock?

ORPH stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., and Point72 Hong Kong Ltd.

How do I buy shares of Orphazyme A/S?

Shares of ORPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Orphazyme A/S's stock price today?

One share of ORPH stock can currently be purchased for approximately $6.52.

How much money does Orphazyme A/S make?

Orphazyme A/S has a market capitalization of $227.89 million. The company earns $-97,010,000.00 in net income (profit) each year or ($3.42) on an earnings per share basis.

How many employees does Orphazyme A/S have?

Orphazyme A/S employs 141 workers across the globe.

What is Orphazyme A/S's official website?

The official website for Orphazyme A/S is

Where are Orphazyme A/S's headquarters?

Orphazyme A/S is headquartered at OLE MAALOES VEJ 3, COPENHAGEN N G7, DK-2200.

How can I contact Orphazyme A/S?

Orphazyme A/S's mailing address is OLE MAALOES VEJ 3, COPENHAGEN N G7, DK-2200. The company can be reached via phone at 45 39 17 82 72 or via email at [email protected]

This page was last updated on 6/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.